Acquired
ALK
and
RET
Gene Fusions as Mechanisms of Resistance to Osimertinib in
EGFR
-Mutant Lung Cancers
JCO Precis Oncol
.
2018:2:PO.18.00126.
doi: 10.1200/PO.18.00126.
Epub 2018 Sep 4.
Authors
Michael Offin
1
,
Romel Somwar
2
,
Natasha Rekhtman
2
,
Ryma Benayed
2
,
Jason C Chang
2
,
Andrew Plodkowski
2
,
Allan J W Lui
3
,
Juliana Eng
1
,
Marc Rosenblum
2
,
Bob T Li
1
,
Gregory J Riely
1
,
Charles M Rudin
1
,
Mark G Kris
1
,
William Travis
2
,
Alexander Drilon
1
,
Maria E Arcila
2
,
Marc Ladanyi
2
,
Helena A Yu
1
Affiliations
1
Memorial Sloan Kettering Cancer Center; Weill Cornell Medical College, New York, NY.
2
Memorial Sloan Kettering Cancer Center.
3
Memorial Sloan Kettering Cancer Center; The Chinese University of Hong Kong, Sha Tin New Town, Hong Kong Special Administrative Region, China.
PMID:
30957057
PMCID:
PMC6447364
DOI:
10.1200/PO.18.00126
No abstract available
Grants and funding
P30 CA008748/CA/NCI NIH HHS/United States
R25 CA020449/CA/NCI NIH HHS/United States
T32 CA009207/CA/NCI NIH HHS/United States